Fintel reports that on October 20, 2025, Needham reiterated coverage of Moderna (NasdaqGS:MRNA) with a Hold recommendation.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large ...

U.S. stocks rise on Monday, with the Dow up 500+ points. Moderna and Cleveland-Cliffs report gains. Most S&P sectors close ...

How is VOO stock faring? The Vanguard S&P 500 ETF is up 1.60% in the past five days and 15.62% year-to-date. Fund Flows and ...

Cidara’s lead candidate, CD388, is a long-acting antiviral prophylactic designed for universal prevention of seasonal and ...

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ( ...

A multi-institutional team led by University of Washington scientists have engineered a new vaccine platform combining mRNA ...

An analysis of patient records suggests that mRNA covid-19 vaccines boost the immune response to cancerous tumours when given ...

The biotech's innovative qualities will come in handy. Long gone are the days when Moderna ( MRNA 2.66%) would generate over ...

Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn ...

Researchers found that among cancer patients getting immunotherapy, those who got an mRNA Covid vaccine within 100 days ...

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next milestone in the execution of its ...